Skip to main content
. 2014 Jul 2;171(17):4112–4124. doi: 10.1111/bph.12757

Figure 6.

Figure 6

GB88 blocks PAR2-induced paw oedema in rats. (A–B) GB88 (10 mg·kg−1 p.o., 3 h prior) inhibited rat paw oedema induced by i.pl. injection of PAR2 agonist, 2f-LIGRLO-NH2 (A, 350 μg) or trypsin (B, 20 μg). (C–D) PKC inhibitor, Gö6983 (1 and 10 μM, intraplanar), inhibited Wistar rat paw oedema induced by i.pl. injection of PAR2 agonist 2f-LIGRLO-NH2 (C, 350 μg) or trypsin (D, 20 μg). Samples were compared with 2f-LIGRLO-NH2 or trypsin-treated controls. Data shown are means ± SEM; n.s. not statistically significant, *P < 0.05, **P < 0.01, ***P < 0.001; significant differences as indicated. Number of rats: A, 2F (n = 9), GB88 (n = 5); B, tryp (n = 9), GB88 (n = 5); C, 2F (n = 3), Go 1 µM (n = 3) and 10 µM (n = 3); D, tryp (n = 3), Go 10 µM (n = 3).